GO:0030552 cAMP binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030552 (cAMP binding) is a molecular function defined as binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate).
• cAMP binding is mediated by conserved cyclic nucleotide-binding domains found in PKA regulatory subunits, Epac guanine nucleotide exchange factors, and cyclic nucleotide-gated (HCN/CNG) ion channels [1, 7, 8].
• cAMP binding can be non-cooperative, as shown for closed pacemaker HCN ion channels, which has implications for the kinetics of channel activation.
• The cAMP/PKA/CREB axis is a central signaling module; cAMP binding to PKA releases catalytic subunits that phosphorylate CREB and drive transcription of target genes such as BCL2 [2, 5, 6].
• cAMP binding also regulates membrane recruitment of Epac1 through its DEP domain, linking cAMP to phosphatidic acid signaling at the plasma membrane.
• Dysregulated cAMP binding and downstream signaling are implicated in cancer, cardiovascular disease, and neurological disorders, making it a target for CRISPR-based functional studies [2, 4, 6].
Description
cAMP binding (GO:0030552) is the molecular function of selectively and non-covalently interacting with cyclic AMP (adenosine 3',5'-cyclophosphate), a universal second messenger [1, 7]. This function is executed by evolutionarily conserved cyclic nucleotide-binding domains (CNBDs) present in several protein families, including the regulatory subunits of cAMP-dependent protein kinase (PKA), exchange proteins directly activated by cAMP (Epac), and cyclic nucleotide-gated ion channels [1, 7, 8]. Because cAMP is produced in response to diverse extracellular signals, cAMP binding serves as a molecular switch that converts transient fluctuations in cyclic nucleotide concentration into changes in protein conformation, enzymatic activity, and ion conductance [1, 5, 8]. For researchers, GO:0030552 provides a precise functional annotation for genes and proteins that directly sense cAMP. It is distinct from upstream adenylyl cyclase activity or downstream phosphorylation events, and it is essential for interpreting signaling networks in development, metabolism, and disease [2, 5, 6]. The availability of high-resolution structures and biophysical assays has made cAMP binding a tractable target for CRISPR-based perturbation, enabling causal tests of its role in physiology and pathology [1, 7, 8]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to describe the definition, mechanism, key genes, disease relevance, and experimental strategies for studying cAMP binding. It is intended for molecular biologists, signaling researchers, and therapeutic developers who need a rigorous, citable overview of GO:0030552.
cAMP binding At A Glance
| GO ID | GO:0030552 |
|---|---|
| GO term | cAMP binding |
| Ontology | molecular_function |
| Definition | Binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate). |
| Synonym | 3',5' cAMP binding; 3',5'-cAMP binding; adenosine 3',5'-cyclophosphate binding; cyclic AMP binding |
| Major function | Sensing intracellular cAMP levels and transducing signals through conformational changes in effector proteins. |
| Representative protein families | PKA regulatory subunits, Epac1/Epac2, HCN channels, CNG channels, and cAMP-responsive transcription regulators. |
| Experimental detection | Radioligand binding, fluorescence polarization, isothermal titration calorimetry, patch-clamp electrophysiology, and structural biology. |
| Related GO terms | cAMP-dependent protein kinase activity (GO:0004691), cAMP-mediated signaling (GO:0019933), cyclic nucleotide binding (GO:0030551). |
What Is GO:0030552?
According to the Gene Ontology, GO:0030552 (cAMP binding) is the molecular function of binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate). It encompasses the selective, non-covalent interaction between a protein domain and the cyclic nucleotide, and it is synonymous with 3',5' cAMP binding, 3',5'-cAMP binding, adenosine 3',5'-cyclophosphate binding, and cyclic AMP binding. This function is typically mediated by cyclic nucleotide-binding domains (CNBDs) and is experimentally detected by methods such as equilibrium dialysis, fluorescence polarization, isothermal titration calorimetry, and electrophysiological recordings of channel modulation [1, 3, 7].
Why Is cAMP binding Important in Cell Biology?
cAMP binding is a fundamental node in signal transduction because it directly couples changes in intracellular cAMP concentration to the activity of kinases, exchange factors, and ion channels. This function underlies diverse physiological processes, including cardiac pacemaking, neuronal excitability, hormone secretion, and gene expression [1, 2, 5, 6, 8]. Because cAMP binding is often the first step in these cascades, its dysregulation can propagate to disease states such as cancer, heart failure, and neurological disorders, making it a high-value target for functional genomics and therapeutic intervention [2, 4, 6].
• cAMP binding is the molecular trigger for PKA activation, which phosphorylates CREB and other substrates to control transcription [2, 5].
• It regulates the activity of Epac1/Epac2 guanine nucleotide exchange factors, which control Ras-family GTPases and cell adhesion.
• It modulates HCN and CNG ion channels, influencing cardiac pacemaker activity and neuronal firing.
• Non-cooperative cAMP binding to closed HCN channels shapes the kinetics of channel opening, which is relevant for heart rate control.
• Dysregulated cAMP binding contributes to cancer cell proliferation and survival through the cAMP/PKA/CREB/BCL2 axis.
• It is involved in vasopressin signaling and water homeostasis, with implications for renal and cardiovascular physiology.
• cAMP binding is a target for pharmacological modulators, including cAMP analogs and phosphodiesterase inhibitors [5, 8].
• CRISPR-based knockout or point mutation of cAMP-binding domains enables causal dissection of signaling pathways [1, 7, 8].
• It is a key annotation for interpreting transcriptomic and proteomic data in signaling studies [2, 5].
• Understanding cAMP binding supports the development of precision therapeutics for diseases with aberrant cAMP signaling [4, 6].
Molecular Mechanism of cAMP binding
Recognition and Binding of cAMP by Cyclic Nucleotide-Binding Domains
In simple terms: Proteins that sense cAMP have a pocket that fits cAMP like a lock and key.
cAMP binding is mediated by cyclic nucleotide-binding domains (CNBDs), which are conserved structural modules found in PKA regulatory subunits, Epac proteins, and cyclic nucleotide-gated channels [1, 7, 8]. The CNBD forms a beta-barrel-like pocket that specifically recognizes the adenine ring and the cyclic phosphate moiety of cAMP, discriminating it from other nucleotides. In PKA type I and type II regulatory subunits, the CNBDs are arranged in tandem, and cAMP binding induces conformational changes that release the catalytic subunits. In HCN pacemaker channels, cAMP binding to the CNBD in the C-terminal region modulates channel opening, and recent work shows that binding to closed channels is non-cooperative. In Epac1, cAMP binding relieves autoinhibition and exposes the DEP domain for membrane interaction.
Conformational Switch and Effector Activation
In simple terms: When cAMP binds, the protein changes shape and turns on its activity.
The binding event triggers allosteric changes that propagate from the CNBD to effector domains. In PKA, cAMP binding to the regulatory subunits causes dissociation of the holoenzyme, releasing active catalytic subunits that phosphorylate substrates such as CREB [2, 5]. In Epac1, cAMP binding promotes a conformational change that allows the DEP domain to bind phosphatidic acid at the plasma membrane, thereby recruiting the exchange factor to sites of Ras GTPase activation. In HCN channels, cAMP binding shifts the voltage dependence of activation, increasing channel opening at physiological voltages. These examples illustrate how a single binding event can be translated into diverse cellular outputs.
Non-Cooperative Binding in Pacemaker Channels
In simple terms: In some channels, the first cAMP molecule binds without making it easier or harder for the next one to bind.
White et al. (2021) demonstrated that cAMP binding to closed HCN pacemaker ion channels is non-cooperative, meaning that the binding of one cAMP molecule does not alter the affinity for subsequent molecules. This contrasts with cooperative binding observed in some other CNBD-containing proteins and has important implications for the kinetics of channel activation during repetitive firing. The study used electrophysiological and biochemical approaches to quantify binding and gating, providing a quantitative framework for understanding how cAMP modulates pacemaker currents.
Integration with Downstream Signaling Pathways
In simple terms: cAMP binding sets off a chain reaction that changes gene expression and cell behavior.
Once cAMP binds to its effectors, the signal is propagated through multiple pathways. The cAMP/PKA/CREB axis is a well-characterized route in which PKA phosphorylates CREB, leading to recruitment of coactivators and transcription of target genes such as BCL2 [2, 5, 6]. In neurons, TAFA2 promotes survival by binding to ADGRL1 and activating cAMP/PKA/CREB/BCL2 signaling, highlighting the role of cAMP binding in neuroprotection. cAMP also regulates mitochondrial biogenesis through CREB-dependent expression of respiratory chain proteins. These interconnected pathways underscore the centrality of cAMP binding in cellular decision-making.
Regulation by Phosphodiesterases and Subcellular Localization
In simple terms: Enzymes that degrade cAMP and the location of proteins control how strong and how long the signal lasts.
The duration and amplitude of cAMP binding are tightly controlled by phosphodiesterases (PDEs), which hydrolyze cAMP and terminate the signal [5, 8]. Subcellular compartmentalization further regulates cAMP binding; for example, Epac1 is recruited to the plasma membrane through its DEP domain, where it interacts with phosphatidic acid and accesses localized cAMP pools. In Dictyostelium discoideum, oscillatory cAMP binding to cell surface receptors coordinates chemotaxis and development, illustrating evolutionary conservation of this regulatory logic. These mechanisms ensure that cAMP binding is spatially and temporally precise.
Key Genes Involved in GO:0030552 cAMP binding
The following genes encode proteins that directly bind cAMP or are central to cAMP-binding-dependent signaling, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKAR1A | Type I regulatory subunit of PKA; binds cAMP to release catalytic subunits | Mutations cause Carney complex; target for cAMP signaling studies |
| PRKAR2A | Type II regulatory subunit of PKA; binds cAMP with distinct kinetics | Isoform-specific functions in cardiac and neuronal signaling |
| PRKAR2B | Type II regulatory subunit of PKA; regulates PKA localization | Role in metabolic and reproductive tissues |
| PRKACA | Catalytic subunit of PKA; activated upon cAMP binding to regulatory subunits | Oncogenic fusions in adrenal and other tumors [2, 5] |
| PRKACB | Catalytic subunit of PKA; mediates CREB phosphorylation | Implicated in neuronal plasticity and cancer [2, 5] |
| CREB1 | Transcription factor phosphorylated by PKA after cAMP binding | Central to cAMP response element (CRE)-mediated gene expression [2, 5] |
| EPAC1 (RAPGEF3) | cAMP-activated guanine nucleotide exchange factor for Rap GTPases | Regulates cell adhesion, migration, and membrane recruitment |
| EPAC2 (RAPGEF4) | cAMP-activated GEF for Rap GTPases | Roles in insulin secretion and neuronal signaling |
| HCN1 | Hyperpolarization-activated cyclic nucleotide-gated channel; binds cAMP | Pacemaker current in neurons and heart |
| HCN2 | HCN channel isoform; cAMP binding modulates gating | Cardiac pacemaking and epilepsy |
| HCN4 | HCN channel isoform; high cAMP sensitivity | Sinoatrial node function and bradycardia |
| CNGA1 | Cyclic nucleotide-gated channel subunit; binds cAMP/cGMP | Phototransduction and olfactory signaling |
| CNGB1 | Cyclic nucleotide-gated channel subunit; modulates ligand sensitivity | Retinal and olfactory function |
| ADGRL1 | Adhesion GPCR that signals through cAMP/PKA/CREB | Neuronal survival and TAFA2 signaling |
| TAFA2 | Neuronal survival factor that activates cAMP/PKA/CREB/BCL2 | Neuroprotection and apoptosis suppression |
| BCL2 | Anti-apoptotic protein upregulated by cAMP/CREB signaling | Cell survival and cancer |
| AVPR2 | Vasopressin receptor that stimulates cAMP production | Water homeostasis and nephrogenic diabetes insipidus |
| ADCYAP1R1 | PACAP receptor coupled to cAMP signaling | Neuroendocrine and stress responses |
How Is cAMP binding Regulated?
cAMP binding is regulated at multiple levels. The availability of cAMP is controlled by adenylyl cyclases, which synthesize it, and by phosphodiesterases, which degrade it [5, 8]. Compartmentalization of these enzymes creates localized cAMP microdomains that selectively engage different cAMP-binding proteins. In addition, post-translational modifications and protein-protein interactions can modulate the affinity of CNBDs for cAMP; for example, the DEP domain of Epac1 mediates membrane recruitment that influences access to cAMP pools. In HCN channels, voltage-dependent gating and cAMP binding are allosterically coupled, and binding to closed channels is non-cooperative. These regulatory layers ensure that cAMP binding is context-dependent and precisely tuned to cellular needs.
cAMP binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKAR1A | Carney complex, endocrine tumors | Knockout or point-mutation cell lines to study PKA activation |
| HCN4 | Bradycardia, arrhythmia | Knock-in of cAMP-binding domain mutations in cardiomyocytes |
| ADGRL1 | Neurodegeneration, neuronal survival | Overexpression or knockout in neuronal cells to test TAFA2 signaling |
| AVPR2 | Nephrogenic diabetes insipidus | Knockout in renal epithelial cells to assess cAMP responses |
| EPAC1 (RAPGEF3) | Cancer, cell adhesion | Knockout or point mutation to dissect DEP domain function |
cAMP Binding in Cancer
Dysregulated cAMP binding and downstream PKA/CREB signaling contribute to cancer cell proliferation and survival. The cAMP/PKA/CREB/BCL2 axis promotes anti-apoptotic gene expression, and its activation by factors such as TAFA2 through ADGRL1 supports neuronal survival but can also be hijacked in tumors. Mutations in PKA subunits, including PRKAR1A, are associated with Carney complex and endocrine tumors. Targeting cAMP-binding domains or their downstream effectors is an active area of therapeutic research [2, 6].
cAMP Binding in Cardiovascular Disease
cAMP binding to HCN channels regulates cardiac pacemaker activity, and non-cooperative binding to closed channels influences the kinetics of pacemaker currents. Altered cAMP signaling is implicated in arrhythmias and heart failure, where changes in HCN channel expression or cAMP sensitivity can affect heart rate. Vasopressin signaling through AVPR2, which elevates cAMP, is critical for water homeostasis and is linked to cardiovascular and renal disorders.
cAMP Binding in Neurological Disorders
In neurons, cAMP binding to PKA and Epac proteins modulates synaptic plasticity, survival, and excitability [2, 5, 6]. TAFA2 suppresses apoptosis through ADGRL1 and cAMP/PKA/CREB/BCL2 signaling, suggesting that impaired cAMP binding may contribute to neurodegeneration. HCN channels in the brain influence neuronal firing and are implicated in epilepsy and pain. These findings position cAMP binding as a potential target for neuroprotective strategies.
cAMP Binding in Metabolic and Endocrine Disorders
cAMP binding is central to hormone signaling, including vasopressin-mediated water reabsorption and insulin secretion [4, 8]. Epac2, a cAMP-binding protein, regulates insulin granule exocytosis, and its dysfunction may contribute to diabetes. PKA regulatory subunit mutations can cause endocrine neoplasia and metabolic dysregulation. Understanding cAMP binding in these contexts may inform precision therapies [4, 8].
From cAMP binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene directly bind cAMP? | Recombinant protein with CNBD and radioligand binding assay [1, 7] |
| What is the effect of a disease-associated point mutation on cAMP binding? | CRISPR point-mutation knock-in cell line [1, 7] |
| How does cAMP binding affect downstream transcription? | Knockout of cAMP-binding protein followed by RNA-seq and CREB reporter assays [2, 5] |
| Does cAMP binding regulate ion channel gating? | Patch-clamp electrophysiology in cells expressing wild-type or mutant channels |
| Where does cAMP binding occur in the cell? | Tagged knock-in with fluorescent protein and live-cell imaging |
| Can overexpression of a cAMP-binding protein drive survival? | Overexpression cell model with apoptosis assays |
How to Study the cAMP binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct cAMP binding affinity and stoichiometry | Characterization of CNBD mutants [1, 3] |
| Fluorescence polarization | Binding-induced changes in molecular rotation | High-throughput screening of cAMP analogs |
| Isothermal titration calorimetry | Thermodynamics of cAMP binding | Cooperativity and affinity studies |
| Patch-clamp electrophysiology | Functional modulation of ion channels by cAMP | HCN/CNG channel gating |
| CRE-luciferase reporter | Transcriptional activity downstream of cAMP/PKA | CREB activation assays [2, 5] |
| RNA-seq | Global gene expression changes | Pathway analysis after cAMP binding perturbation [2, 5] |
| Live-cell FRET imaging | Real-time cAMP dynamics and localization | Compartmentalized cAMP signaling |
| Western blot | Phosphorylation of CREB and other substrates | Validation of PKA activation [2, 6] |
Biophysical and Biochemical Binding Assays
Direct measurement of cAMP binding can be achieved using radioligand binding assays, fluorescence polarization, or isothermal titration calorimetry [1, 3, 7]. These methods quantify affinity, stoichiometry, and cooperativity. For example, White et al. used biochemical and electrophysiological approaches to demonstrate non-cooperative cAMP binding to HCN channels. King et al. characterized oscillatory cAMP binding in Dictyostelium using membrane preparations. Such assays are essential for validating CNBD function and the impact of mutations.
Electrophysiology for Channel Modulation
Patch-clamp electrophysiology measures the functional consequences of cAMP binding on ion channels such as HCN and CNG channels. By applying cAMP to inside-out patches or using cAMP analogs, researchers can quantify shifts in voltage dependence and changes in current kinetics. This approach is particularly powerful for studying non-cooperative binding and allosteric coupling.
Transcriptional and Signaling Readouts
Downstream effects of cAMP binding can be monitored using luciferase reporters driven by cAMP response elements (CRE), Western blotting for phosphorylated CREB, and RNA-seq to profile target genes [2, 5, 6]. The cAMP/PKA/CREB/BCL2 axis is a common readout, and changes in BCL2 expression can indicate pathway activation. These methods link binding events to gene expression programs [2, 5].
Imaging and Subcellular Localization
Fluorescently tagged cAMP-binding proteins, such as Epac1, can be used to visualize subcellular localization and membrane recruitment in live cells. FRET-based cAMP sensors provide real-time readouts of cAMP dynamics in specific compartments. These imaging approaches complement biochemical assays by revealing where and when cAMP binding occurs.
How CRISPR Can Be Used to Study GO:0030552 cAMP binding
Knockout
CRISPR knockout of genes encoding cAMP-binding proteins, such as PRKAR1A or EPAC1, can abolish cAMP sensing and reveal downstream consequences [7, 8]. Knockout cell models are useful for identifying which pathways depend on a specific cAMP-binding protein and for validating drug targets [2, 6].
Point Mutation
Point mutations in the cyclic nucleotide-binding domain can selectively disrupt cAMP binding without affecting protein stability. CRISPR-mediated knock-in of such mutations allows precise testing of binding-dependent functions, as exemplified by studies of HCN channel gating [1, 7].
Knock-in
Knock-in of epitope tags or fluorescent proteins into endogenous cAMP-binding genes enables visualization and purification of native protein complexes. This approach preserves endogenous regulation and is ideal for studying subcellular localization and interaction partners.
Overexpression
Overexpression of wild-type or mutant cAMP-binding proteins can amplify signaling and reveal gain-of-function phenotypes. For example, overexpression of TAFA2 or ADGRL1 can activate cAMP/PKA/CREB/BCL2 signaling and suppress apoptosis. Overexpression models are valuable for screening downstream effectors and testing therapeutic hypotheses.
How EDITGENE Supports cAMP binding Research
Researchers studying cAMP binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that enable such causal inferences.
Contact EDITGENE today to design your custom CRISPR model for cAMP binding research.
Frequently Asked Questions About cAMP binding
What is cAMP binding?
cAMP binding (GO:0030552) is the molecular function of binding to cyclic AMP (adenosine 3',5'-cyclophosphate), typically mediated by cyclic nucleotide-binding domains in proteins such as PKA regulatory subunits, Epac, and HCN channels [1, 7, 8].
What genes are involved in cAMP binding?
Key genes include PRKAR1A, PRKAR2A, PRKAR2B, PRKACA, PRKACB, CREB1, EPAC1 (RAPGEF3), EPAC2 (RAPGEF4), HCN1, HCN2, HCN4, CNGA1, CNGB1, ADGRL1, TAFA2, BCL2, AVPR2, and ADCYAP1R1 [1, 2, 4, 5, 6, 7, 8].
What is the GO ID for cAMP binding?
The Gene Ontology ID for cAMP binding is GO:0030552.
Is cAMP binding cooperative?
Not always; cAMP binding to closed HCN pacemaker ion channels is non-cooperative, as shown by White et al. (2021).
What diseases are associated with cAMP binding?
Dysregulated cAMP binding is implicated in cancer, cardiovascular disease, neurological disorders, and metabolic/endocrine disorders [1, 2, 4, 6, 7, 8].
How can I study cAMP binding in the lab?
Common methods include radioligand binding assays, fluorescence polarization, isothermal titration calorimetry, patch-clamp electrophysiology, CRE-luciferase reporters, RNA-seq, and live-cell imaging [1, 2, 3, 5, 7, 8].
What is the role of cAMP binding in PKA activation?
cAMP binding to PKA regulatory subunits causes dissociation of the holoenzyme, releasing active catalytic subunits that phosphorylate CREB and other substrates [2, 5, 7].
How does Epac1 respond to cAMP binding?
cAMP binding to Epac1 relieves autoinhibition and promotes DEP domain-mediated recruitment to phosphatidic acid at the plasma membrane.
Can CRISPR be used to study cAMP binding?
Yes; CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of cAMP-binding proteins and their downstream effects [1, 6, 7, 8].
What is the definition of cAMP binding according to QuickGO?
QuickGO defines GO:0030552 as binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate).
Conclusion
cAMP binding (GO:0030552) is a central molecular function that translates fluctuations in cyclic AMP into diverse cellular responses through PKA, Epac, and cyclic nucleotide-gated channels [1, 7, 8]. Its non-cooperative binding in pacemaker channels and its role in the cAMP/PKA/CREB/BCL2 axis highlight its importance in physiology and disease [1, 2, 6]. Continued research using CRISPR-based models will clarify how specific binding events contribute to health and disease, and EDITGENE is positioned to support these efforts with tailored cell engineering services.
References
- 1. White DS et al.. 2021. cAMP binding to closed pacemaker ion channels is non-cooperative.. Nature 595(7868):606-610 PMID: 34194042
- 2. De Rasmo D et al.. 2010. cAMP/Ca2+ response element-binding protein plays a central role in the biogenesis of respiratory chain proteins in mammalian cells.. IUBMB Life 62(6):447-52 PMID: 20503437
- 3. King AC et al.. 1979. Properties of the oscillatory cAMP binding component of Dictyostelium discoideum cells and isolated plasma membranes.. J Biol Chem 254(15):7168-76 PMID: 222758
- 4. Cuzzo B et al.. 2026. Physiology, Vasopressin.. PMID: 30252325
- 5. Roesler WJ. 2000. What is a cAMP response unit?. Mol Cell Endocrinol 162(1-2):1-7 PMID: 10854692
- 6. Liang H et al.. 2023. Neuronal survival factor TAFA2 suppresses apoptosis through binding to ADGRL1 and activating cAMP/PKA/CREB/BCL2 signaling pathway.. Life Sci 334:122241 PMID: 37944639
- 7. Weber IT et al.. 1987. Predicted structures of cAMP binding domains of type I and II regulatory subunits of cAMP-dependent protein kinase.. Biochemistry 26(2):343-51 PMID: 3030405
- 8. Consonni SV et al.. 2012. cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane.. Proc Natl Acad Sci U S A 109(10):3814-9 PMID: 22343288
